Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer

• Publication date

  2000-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1097-0142(20000615)88:12<2782::AID-CNCR17>3.0.CO;2-KPMID 10870061
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FIGO staging of gynecologic cancer

  1999cited by this paper
• FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

  1999cited by this paper
• FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

  1999cited by this paper
• The impact of adjuvant radiotherapy on carcinosarcoma of the uterus.

  1998cited by this paper
• Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study.

  1997cited by this paper
• Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus

  1996cited by this paper
• Cancer staging using the American Joint Committee on Cancer TNM System.

  1995cited by this paper
• A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed müllerian tumors (MMT) of the uterus.

  1995cited by this paper
• Prognostic factors in early‐stage uterine sarcoma: A gynecologic oncology group study

  1993cited by this paper
• Survival of patients with ovarian epithelial carcinomas after second-look laparotomy

  1990cited by this paper
• Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases.

  1990cited by this paper
• Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).

  1989cited by this paper
• Clinicopathologic analysis of uterine malignant mixed müllerian tumors.

  1989influential reference
• Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors.

  1989cited by this paper
• Management of malignant, mixed mesodermal tumors of the uterus.

  1989cited by this paper
• Mixed Mullerian Tumors of the Uterus: A Clinicopathologic Study

  1989cited by this paper
• Mixed mesodermal tumors of the ovary: A clinicopathologic study of 14 cases

  1988cited by this paper
• Prognostic value of peritoneal washings in patients with malignant mixed müllerian tumors of the uterus.

  1986cited by this paper
• Prognostic factors in malignant mesodermal (mullerian) mixed tumors of the uterus.

  1985cited by this paper
• Uterine sarcomas: natural history, treatment and prognosis.

  1978cited by this paper
• Mixed mesodermal sarcoma of the uterus.

  1973cited by this paper
• Carcinosarcoma and Mixed Mesodermal Tumor of the Uterine Corpus: Review of 49 Cases

  1970cited by this paper
• Carcinosarcoma and mixed mesodermal tumor of the uterine corpus. Review of 49 cases.

  1970cited by this paper
• Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus.

  1963cited by this paper

• A rare case report of uterine carcinosarcoma with bilateral ovarian Brenner tumors

  2025cites this paper
• Prognostic indicators of recurrence and treatment-free interval in uterine carcinosarcoma.

  2025cites this paper
• Establishment and comparison of three sublines from a human uterine carcinosarcoma cell line, ESCA

  2025cites this paper
• Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma

  2025cites this paper
• Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies.

  2024cites this paper
• Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy.

  2023cites this paper
• Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival

  2023cites this paper
• Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience

  2023cites this paper
• Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: A proposal for HER2-targeted therapy specimen selection.

  2023cites this paper
• Uterine carcinosarcoma: A 10-year single institution experience

  2022cites this paper
• Malignant diseases of the uterus

  2022cites this paper
• Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine Carcinosarcoma

  2022cites this paper
• Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma.

  2022cites this paper
• Radiotherapy-induced uterine cacinosarcoma: A case report and review of the literature

  2022cites this paper
• Uterine Sarcoma: Retrospective Study From A Single institute

  2022cites this paper
• Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy

  2021cites this paper
• Uterine Carcinosarcoma: A Plan for Treatment

  2021cites this paper
• HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line

  2021cites this paper
• Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma

  2021cites this paper
• A Real-World Study on Diagnosis and Treatment of Uterine Sarcoma in Western China

  2020cites this paper
• Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

  2020cites this paper
• Non-Endometrioid Histologies: What Is New?

  2020cites this paper
• Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.

  2020cites this paper
• Folate Receptor Alpha Is Preferentially Expressed in the Carcinoma Component of Endometrial Carcinosarcomas: A Potential Target for Adjuvant Therapy

  2020cites this paper
• Recent Advances in Endometrial Cancer

  2020cites this paper
• A Study of Prognostic Factors of Chinese Patients with Gynecologic Tract Carcinosarcomas Prognosis of Gynecologic Carcinosarcomas

  2020cites this paper
• DNA Mismatch Repair–deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas

  2020cites this paper
• Molecular variations in uterine carcinosarcomas identify therapeutic opportunities

  2020cites this paper
• Uterine Sarcomas: 10 Years of Experience at a Single Institution

  2019cites this paper
• Uterine carcinosarcoma: A 10-Year single institution experience

  2019cites this paper
• Endometrial Carcinoma

  2019cites this paper
• Uterine Carcinosarcomas.

  2019cites this paper
• Gynecologic Tumor PET/CT Imaging

  2019cites this paper
• Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?

  2019cites this paper
• Uterine carcinosarcoma: a primer for radiologists

  2019cites this paper
• A Successful Case of Long Time Management of a Uterine Carcinosarcoma with Liver Metastases

  2019cites this paper
• A Case of Cryofibrinogen Associated Glomerulonephritis

  2019cites this paper
• ♀ Mixed Epithelial and Mesenchymal Tumors of the Uterus

  2019cites this paper
• Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework

  2018cites this paper
• Adenocarcinoma, Carcinosarcoma, and Other Epithelial Tumors of the Endometrium

  2018cites this paper
• Maligne epitheliale Tumoren des Corpus uteri (einschließlich des Karzinosarkoms)

  2018cites this paper
• Gynecologic Cancers: Molecular Updates 2018.

  2018cites this paper
• Caracterización molecular de los carcinosarcomas de endometrio.

  2018cites this paper
• Uterine Cancer

  2018cites this paper
• Uterine sarcomas

  2018cites this paper
• Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature

  2018cites this paper
• Prognostic value of metabolic parameters determined by preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma

  2017cites this paper
• Integrated Molecular Characterization of Uterine Carcinosarcoma.

  2017cites this paper
• Biphasic malignant tumours of the abdominal cavity

  2017cites this paper
• Is Omentectomy Necessary for Non-Endometrioid Endometrial Cancer

  2017cites this paper
• Uterine Sarcomas: The Latest Approaches for These Rare but Potentially Deadly Tumors.

  2017cites this paper
• Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases

  2017cites this paper
• Endometrial Cancer Genomics

  2017cites this paper
• Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS

  2017cites this paper
• Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma

  2017cites this paper
• New therapies for advanced, recurrent, and metastatic endometrial cancers

  2017cites this paper
• Carcinosarcoma of the Uterine Corpus – a Case Report and Brief Review of the Literature

  2016cites this paper
• The retrospective analysis of patients with uterine sarcomas: A single-center experience.

  2016cites this paper
• [New features in the 2014 WHO classification of uterine neoplasms].

  2016cites this paper
• PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker

  2016cites this paper
• Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.

  2016cites this paper
• Uterine Carcinosarcoma after Pelvic Radiotherapy

  2016cites this paper
• Neues in der WHO-Klassifikation 2014 der Tumoren des Corpus uteri

  2016cites this paper
• [Uterine Carcinosarcoma: Clinicopathological Features and Prognostic Factors].

  2016cites this paper
• Therapeutic Modalities in Early-Stage Uterine Papillary Serous Carcinomas, Carcinosarcomas, Clear-Cell and Mixed Histology Carcinomas: Treatment of Choice Is Combined Chemotherapy and Radiation

  2016cites this paper
• Management of Uterine Sarcomas

  2016cites this paper
• Uterine Malignant Mixed Mullerian Tumour - Revisited In Newer Lights: A Case Report from a Tertiary Care Centre

  2015cites this paper
• Surveillance of Uterine Sarcomas

  2015cites this paper
• Uterine sarcomas

  2015cites this paper
• Uterine and Ovary Carcinosarcomas: Outcome, Prognosis Factors, and Adjuvant Therapy

  2015cites this paper
• Rare uterine cancer: carcinosarcomas. Review from histology to treatment.

  2015cites this paper
• Uterine carcinosarcoma: A review of the literature.

  2015cites this paper
• Atypical Findings on Cervicovaginal Smears Correlate with Cervical Involvement by Malignant Mixed Müllerian Tumors of the Uterus

  2015cites this paper
• Surgical Management of Uterine Sarcoma

  2015cites this paper
• Carcinosarcomas: tumors in transition?

  2015cites this paper
• Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping

  2015cites this paper
• Review of Recommended Treatment of Uterine Carcinosarcoma

  2015cites this paper
• Prognostic Factors in Uterine Cancer

  2015cites this paper
• Management of uterine sarcoma

  2014cites this paper
• The role of lymphadenectomy in uterine sarcoma: a clinical practical approach based on retrospective analysis.

  2014cites this paper
• Gynecologic oncologic imaging with PET/CT.

  2014cites this paper
• Black race independently predicts worse survival in uterine carcinosarcoma.

  2014cites this paper
• Clinicopathological features and prognostic factors of the uterine sarcomas: 20 years of experience at Cukurova University.

  2014cites this paper
• Role of p53 Pathway Alterations in Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumors)

  2014cites this paper
• Spontaneous Rupture of the Uterus Associated with Mixed Mullerian Tumours

  2013cites this paper
• Carcinosarcoma of Uterus – A highly Aggressive Tumour – A Case Report

  2013cites this paper
• Gynecologic sarcoma: a clinico-pathological review.

  2013cites this paper
• Factores pronósticos para sobrevida en pacientes con carcinosarcoma uterino

  2013cites this paper
• Prognostic determinants in patients with uterine and ovarian carcinosarcoma.

  2013cites this paper
• Gynecologic cancers: molecular updates.

  2013cites this paper
• Case Reports Carcinosarcoma of Uterus – A highly Aggressive Tumour – A Case Report

  2013cites this paper
• Case 14-2013

  2013cites this paper
• Erkrankungen des Endometriums

  2013cites this paper
• Case records of the Massachusetts General Hospital. Case 14-2013. A 70-year-old woman with vaginal bleeding.

  2013cites this paper
• Uterine Sarcoma: A review of the literature

  2012cites this paper
• 32-Neoplastic Diseases of the Uterus

  2012cites this paper
• Prognostic Value of Alternative Lengthening of Telomeres–Associated Biomarkers in Uterine Sarcoma and Uterine Carcinosarcoma

  2012cites this paper
• Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: clinicoimmunohistochemical and histogenetic characteristics.

  2012cites this paper
• Uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma : Epidemiological, clinical and prognostic aspects

  2012cites this paper
• Tumors of the uterine corpus

  2012cites this paper